Opipramol for the Treatment of Generalized Anxiety Disorder: A Placebo-Controlled Trial Including an Alprazolam-Treated Group

@article{Mller2001OpipramolFT,
  title={Opipramol for the Treatment of Generalized Anxiety Disorder: A Placebo-Controlled Trial Including an Alprazolam-Treated Group},
  author={H. J. M{\"o}ller and Hans Peter Volz and Ingrid W. Reimann and K. D. Stoll},
  journal={Journal of Clinical Psychopharmacology},
  year={2001},
  volume={21},
  pages={59-65}
}
Opipramol, a drug widely prescribed in Germany, is a tricyclic compound with no reuptake-inhibiting properties. However, it has pronounced D2-, 5-HT2-, and H1-blocking potential and high affinity to sigma receptors (sigma-1 and sigma-2). In early controlled trials, anxiolytic effects were revealed. However, those studies were performed before the concept of generalized anxiety disorder (GAD) was established. Because of the interesting receptor-binding profile and promising results of the early… 
Psychopharmacotherapy of somatoform disorders: effects of opipramol on symptoms of somatization, anxiety, and depression
TLDR
The well-tolerated anxiolytic opipramol is the first psychotropic drug with proven efficacy in somatoform disorders with effects on symptoms of somatization, anxiety, and depression.
Clinical pharmacology, clinical efficacy, and behavioral toxicity of alprazolam: a review of the literature.
TLDR
An exhaustive review of the literature showed that alprazolam is significantly superior to placebo, and is at least equally effective in the relief of symptoms as tricyclic antidepressants (TCAs) such as imipramine.
[Update Opipramol].
TLDR
In view of the limited availability of (pharmacologic) treatment options for generalized anxiety disorder and particularly somatoform disorders, opipramol should be considered in the treatment of these entities.
Kava in generalized anxiety disorder: three placebo-controlled trials
TLDR
In the pooled analyses, no effects were found for kava, while a significant effect in favor of placebo was observed in participants with higher anxiety at baseline, and all of the treatments were well tolerated.
Modern indications for the use of opipramol.
TLDR
An analysis of the data from literature shows however that opipramol is an important drug still very useful in different clinical conditions.
OPIPRAMOL VERSUS ESCITALOPRAM IN THE TREATMENT OF GENERALIZED ANXIETY DISORDER
TLDR
Opipramol is effective in the treatment of GAD and it is as effective as escitalopram and all the adverse events in both the group were mild to moderate.
Escitalopram in the treatment of generalized anxiety disorder
TLDR
Escitalopram is effective and well tolerated in both the short- and long-term treatment of generalized anxiety disorder, and has advantages over benzodiazepines and the selective serotonin reuptake inhibitor paroxetine.
Antiepileptic Drugs in the Treatment of Anxiety Disorders
TLDR
Antiepileptic drugs may have a place in the treatment of anxiety disorders; however, further investigation is warranted to determine in what circumstances they should be used as monotherapy or as augmenting agents in individuals who are partially or non-responsive to conventional therapy.
Novel Opipramol-Baclofen Combination Alleviates Depression and Craving and Facilitates Recovery From Substance Use Disorder—An Animal Model and a Human Study
TLDR
A novel combination of opipramol and baclofen (O/B) which is known to attenuate anxiety and depression is suggested for the facilitation of recovery from SUDs and comorbid mood/anxiety disorders that may facilitate their rehabilitation.
Effectiveness and safety of long-term benzodiazepine use in anxiety disorders: a systematic review and meta-analysis.
TLDR
This study indicates that for those who respond to an initial 8-week treatment, continuing BZDs is equivalent to antidepressants in efficacy and safety, however, the limited number of studies warranted further investigations of the long-term effectiveness and safety of BzDs.
...
...

References

SHOWING 1-10 OF 14 REFERENCES
Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam.
TLDR
The results of the study need replication, but suggest a potentially important role for antidepressants, particularly imipramine, in patients suffering from GAD.
A Comparative Trial of Opipramol and Chlordiazepoxide in the Treatment of Anxiety
TLDR
Although opipramol appeared to give more relief of somatic anxiety, the difference was not statistically significant and the total number of side effects recorded was similar on both drugs although drowsiness occurred twice as frequently on chlordiazepoxide as it did on opipramsol.
A COMPARISON BETWEEN DIAZEPAM, DIXYRAZINE, OPRIPRAMOL AND PLACEBO IN ANXIETY STATES
TLDR
Diazepam, an iminostilben derivate with piperazine chain which was originally introduced as an antidepressant but later claimed to belong to the anxiolytics, has proved superior to placebo and equal to chlordiazepoxide.
Drug Treatment of Anxiety: A Controlled Study of Opipramol and Chlordiazepoxide
TLDR
Following the introduction of imipramine hydrochloride as the first specific thymoleptic drug, further compounds related to the iminodibenzyl family were developed: opipramol, which has the formula 4-[3-(5H-dibenzo[b,f] azepine-5-yl)-propyl]-1-hydroxyethyl)-piperazine-dihydrochloride (Schindler and Blattner, 1961).
A Comparative Trial of Insidon and Stelazine in the Treatment of Anxiety
TLDR
In a double-blind comparison of opipramol and trifluoperazine the symptom ‘anxiety’ was found to be statistically more improved in the opipramsol group of patients.
Blockade of hippocampal dopamine (da) receptors: A tool for antipsychotics with low extrapyramidal side effects
[3H]opipramol labels a novel binding site and sigma receptors in rat brain membranes.
TLDR
Because certain of these drugs are more potent at the haloperidol-resistant opipramol site than in exerting any other action, it is possible that this opipramsol-selective site may mediate their therapeutic effects.
...
...